Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SCRT + CAPOX for LARC
NCT06765616Phase 2Recruiting
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in rectal cancer. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06765616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765616.